BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB Jr, Lynch PM, Wu TT, Smythe R, Vaporciyan A. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004;100:2347-2354. [PMID: 15160337 DOI: 10.1002/cncr.20284] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Wada Y, Anbai A, Takagi N, Kumagai S, Okuyama E, Nanjo H, Sato Y, Motoyama S, Hashimoto M. Outcomes of Definitive Chemoradiotherapy for Stage IVa (T4b vs. N4) Esophageal Squamous Cell Carcinoma Based on the Japanese Classification System: A Retrospective Single-Center Study. Cancers (Basel) 2020;13:E8. [PMID: 33375169 DOI: 10.3390/cancers13010008] [Reference Citation Analysis]
2 Zhu Z, Gong YB, Xu HM. Neoadjuvant therapy strategies for advanced gastric cancer: Current innovations and future challenges. Chronic Dis Transl Med 2020;6:147-57. [PMID: 32908968 DOI: 10.1016/j.cdtm.2020.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Komatsu S, Ichikawa D, Kawaguchi T, Takeshita H, Miyamae M, Ohashi T, Okajima W, Imamura T, Kiuchi J, Arita T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Otsuji E. Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma. Oncotarget. 2016;7:62034-62048. [PMID: 27566562 DOI: 10.18632/oncotarget.11500] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
4 van Rossum PSN, Fried DV, Zhang L, Hofstetter WL, Ho L, Meijer GJ, Carter BW, Court LE, Lin SH. The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma. Eur J Nucl Med Mol Imaging 2017;44:71-80. [PMID: 27511188 DOI: 10.1007/s00259-016-3478-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
5 Servagi-Vernat S, Créhange G, Roullet B, Guimas V, Maingon P, Puyraveau M, Bosset JF. Phase II Study of a Platinum-Based Adapted Chemotherapy Regimen Combined with Radiotherapy in Patients 75 Years and Older with Esophageal Cancer. Drugs Aging 2015;32:487-93. [PMID: 26038198 DOI: 10.1007/s40266-015-0275-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
6 Kneuertz PJ, Hofstetter WL, Chiang Y, Das P, Blum M, Elimova E, Mansfield P, Ajani J, Badgwell B. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ? Ann Surg Oncol 2016;23:626-32. [DOI: 10.1245/s10434-015-4898-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
7 Choi Y, Oh DY, Kim K, Chie EK, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Ha SW, Bang YJ. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. Cancer Res Treat 2016;48:1045-55. [PMID: 26511805 DOI: 10.4143/crt.2015.226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
8 Rackley T, Leong T, Foo M, Crosby T. Definitive Chemoradiotherapy for Oesophageal Cancer — A Promising Start on an Exciting Journey. Clinical Oncology 2014;26:533-40. [DOI: 10.1016/j.clon.2014.06.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
9 Xu W, Wang S, Chen Q, Zhang Y, Ni P, Wu X, Zhang J, Qiang F, Li A, Røe OD, Xu S, Wang M, Zhang R, Zhou J. TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer. Cell Death Dis 2014;5:e1055. [PMID: 24525731 DOI: 10.1038/cddis.2014.27] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
10 Wood MD, Zaki BI, Gordon SR, Sutton JE Jr, Lisovsky M, Gui J, Bubis JA, Dragnev KH, Rigas JR. Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy. J Thorac Oncol 2013;8:487-94. [PMID: 23370365 DOI: 10.1097/JTO.0b013e3182829bf3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Tomblyn MB, Goldman BH, Thomas CR Jr, Benedetti JK, Lenz HJ, Mehta V, Beeker T, Gold PJ, Abbruzzese JL, Blanke CD; SWOG GI Committee. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). J Thorac Oncol 2012;7:906-12. [PMID: 22481235 DOI: 10.1097/JTO.0b013e31824c7bed] [Cited by in Crossref: 44] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
12 Wo JY, Hong TS, Kachnic LA. Impact of Age and Comorbidities on the Treatment of Gastrointestinal Malignancies. Seminars in Radiation Oncology 2012;22:311-20. [DOI: 10.1016/j.semradonc.2012.05.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
13 Herskovic A, Russell W, Liptay M, Fidler MJ, Al-Sarraf M. Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol. 2012;23:1095-1103. [PMID: 22003242 DOI: 10.1093/annonc/mdr433] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 5.7] [Reference Citation Analysis]
14 Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, Friess H, Hofler H. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253:934-939. [PMID: 21490451 DOI: 10.1097/sla.0b013e318216f449] [Cited by in Crossref: 152] [Cited by in F6Publishing: 100] [Article Influence: 13.8] [Reference Citation Analysis]
15 Swisher SG, Hofstetter W, Komaki R, Correa AM, Erasmus J, Lee JH, Liao Z, Maru D, Mehran R, Patel S. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg. 2010;90:892-898; discussion 898-899. [PMID: 20732514 DOI: 10.1016/j.athoracsur.2010.04.061] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
16 Taguchi M, Nagashio Y, Kihara Y, Hiura M, Abe S, Yamamoto M, Harada M. Three cases of locally advanced pancreatic cancer successfully treated with chemoradiation and chemotherapy. Clin J Gastroenterol 2010;3:186-90. [DOI: 10.1007/s12328-010-0157-x] [Reference Citation Analysis]
17 Wu K, Chen G, Xu Z, Fu X, Qian H, Jiang G. Three-dimensional conformal radiation therapy for squamous cell carcinoma of the esophagus: A prospective phase I/II study. Radiotherapy and Oncology 2009;93:454-7. [DOI: 10.1016/j.radonc.2009.10.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
18 Servagi-Vernat S, Bosset M, Crehange G, Buffet-Miny J, Puyraveau M, Maingon P, Mercier M, Bosset JF. Feasibility of chemoradiotherapy for oesophageal cancer in elderly patients aged >or=75 years: a prospective, single-arm phase II study. Drugs Aging 2009;26:255-62. [PMID: 19358620 DOI: 10.2165/00002512-200926030-00006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
19 Mansour JC, Schwarz RE. Pathologic Response to Preoperative Therapy: Does It Mean What We Think It Means? Ann Surg Oncol 2009;16:1465-79. [DOI: 10.1245/s10434-009-0374-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
20 Tew WP, Radovich D, O'Reilly E, Schwartz G, Schrag D, Saltz LB, Kelsen DP, Kepler S, Ilson DH. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. Invest New Drugs 2009;27:366-73. [PMID: 18956138 DOI: 10.1007/s10637-008-9194-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
21 Yoon HH, Forastiere AA. Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome. Future Oncol 2008;4:413-25. [PMID: 18518766 DOI: 10.2217/14796694.4.3.413] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
22 Farhat FS. A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol 2007;24:137-46. [PMID: 17848736 DOI: 10.1007/BF02698032] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
23 Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans DB, Wolff RA. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007;110:47-55. [PMID: 17538975 DOI: 10.1002/cncr.22735] [Cited by in Crossref: 200] [Cited by in F6Publishing: 183] [Article Influence: 13.3] [Reference Citation Analysis]
24 Aiko S, Yoshizumi Y, Ishizuka T, Sakano T, Kumano I, Sugiura Y, Maehara T. Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy. Dis Esophagus 2007;20:94-101. [PMID: 17439591 DOI: 10.1111/j.1442-2050.2006.00624.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
25 Liao Z, Cox JD, Komaki R. Radiochemotherapy of esophageal cancer. J Thorac Oncol. 2007;2:553-568. [PMID: 17545853 DOI: 10.1097/01.JTO.0000275339.62831.5e] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
26 Hainsworth JD, Meluch AA, Gray JR, Spigel DR, Meng C, Bearden JD, Hermann R, Greco FA. Concurrent chemoradiation followed by esophageal resection vs chemoradiation alone for localized esophageal cancer. Community Oncology 2007;4:431-9. [DOI: 10.1016/s1548-5315(11)70102-4] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
27 Kleinberg L, Gibson MK, Forastiere AA. Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization. Nat Clin Pract Oncol 2007;4:282-94. [PMID: 17464336 DOI: 10.1038/ncponc0796] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
28 Yoon HH, Gibson MK. Combined-modality therapy for esophageal and gastroesophageal junction cancers. Curr Oncol Rep 2007;9:184-92. [DOI: 10.1007/s11912-007-0020-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
29 Gee DW, Rattner DW. Management of gastroesophageal tumors. Oncologist. 2007;12:175-185. [PMID: 17296813 DOI: 10.1634/theoncologist.12-2-175] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
30 Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol. 2007;18:898-902. [PMID: 17351256 DOI: 10.1093/annonc/mdm004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
31 Gao XS, Qiao X, Wu F, Cao L, Meng X, Dong Z, Wang X, Gao G, Wu TT, Komaki R. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys. 2007;67:389-396. [PMID: 17236963 DOI: 10.1016/j.ijrobp.2006.09.015] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 4.9] [Reference Citation Analysis]
32 Ross WA, Alkassab F, Lynch PM, Ayers GD, Ajani J, Lee JH, Bismar M. Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. Gastrointestinal Endoscopy 2007;65:70-6. [DOI: 10.1016/j.gie.2006.04.040] [Cited by in Crossref: 89] [Cited by in F6Publishing: 74] [Article Influence: 5.9] [Reference Citation Analysis]
33 Lowy AM, Firdaus I, Roychowdhury D, Redmond K, Howington JA, Sussman JJ, Safa M, Ahmad SA, Reed MF, Rose P. A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma. Am J Clin Oncol. 2006;29:555-561. [PMID: 17148991 DOI: 10.1097/01.coc.0000233997.36073.8e] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
34 Ilson DH. Cancer of the Gastroesophageal Junction: Combined Modality Therapy. Surgical Oncology Clinics of North America 2006;15:803-24. [DOI: 10.1016/j.soc.2006.07.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
35 Garces CA, McAuliffe PF, Hochwald SN, Cance WG. Neoadjuvant therapy in the treatment of solid tumors. Curr Probl Surg 2006;43:457-551. [PMID: 16860653 DOI: 10.1067/j.cpsurg.2006.04.003] [Reference Citation Analysis]
36 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]
37 Brücher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, Busch R, Zimmermann F, Molls M, Höfler H. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer. 2006;106:2119-2127. [PMID: 16607651 DOI: 10.1002/cncr.21850] [Cited by in Crossref: 107] [Cited by in F6Publishing: 94] [Article Influence: 6.7] [Reference Citation Analysis]
38 Haglof KJ, Popa E, Hochster HS. Recent developments in the clinical activity of topoisomerase-1 inhibitors. Update on Cancer Therapeutics 2006;1:117-45. [DOI: 10.1016/j.uct.2006.05.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
39 Chang JY, Zhang X, Komaki R, Cheung R, Fang B. Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2006;64:1482-94. [PMID: 16580499 DOI: 10.1016/j.ijrobp.2005.11.045] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
40 Ng T, Dipetrillo T, Purviance J, Safran H. Multimodality treatment of esophageal cancer: A review of the current status and future directions. Curr Oncol Rep 2006;8:174-82. [DOI: 10.1007/s11912-006-0017-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
41 Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005;104:2365-2372. [PMID: 16245310 DOI: 10.1002/cncr.21439] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 4.9] [Reference Citation Analysis]
42 Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Wu TT, Swisher SG. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer 2006;107:967-74. [DOI: 10.1002/cncr.22077] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
43 Bosset JF, Lorchel F, Mantion G, Buffet J, Créhange G, Bosset M, Chaigneau L, Servagi S. Radiation and chemoradiation therapy for esophageal adenocarcinoma. J Surg Oncol 2005;92:239-45. [PMID: 16299784 DOI: 10.1002/jso.20365] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
44 Mooney MM. Neoadjuvant and adjuvant chemotherapy for esophageal adenocarcinoma. J Surg Oncol 2005;92:230-8. [PMID: 16299790 DOI: 10.1002/jso.20364] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
45 Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Lahoti S, Lee JH, Bresalier R, Roth JA, Swisher SG. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2006;131:65-72. [PMID: 16399296 DOI: 10.1016/j.jtcvs.2005.08.037] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
46 Forshaw M, Gossage J, Mason R. Neoadjuvant chemotherapy for oesophageal cancer: The need for accurate response prediction and evaluation. The Surgeon 2005;3:373-82. [DOI: 10.1016/s1479-666x(05)80047-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
47 Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh G, Vaporciyan A, Lynch PM, Rice DC, Roth JA, Ajani JA. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 2005;104:1349-55. [PMID: 16130133 DOI: 10.1002/cncr.21346] [Cited by in Crossref: 83] [Cited by in F6Publishing: 88] [Article Influence: 4.9] [Reference Citation Analysis]
48 Lordick F. Neoadjuvante Therapie von Plattenepithelkarzinomen des Ösophagus: Was ist „evidence based“? Chirurg 2005;76:1025-32. [DOI: 10.1007/s00104-005-1098-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
49 Zhao KL, Shi XH, Jiang GL, Yao WQ, Guo XM, Wu GD, Zhu LX. Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squamous cell carcinoma of the esophagus: a phase III randomized study. Int J Radiat Oncol Biol Phys. 2005;62:1014-1020. [PMID: 15990003 DOI: 10.1016/j.ijrobp.2004.12.022] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 2.6] [Reference Citation Analysis]
50 Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347-1355. [PMID: 15719440 DOI: 10.1002/cncr.20916] [Cited by in Crossref: 279] [Cited by in F6Publishing: 282] [Article Influence: 16.4] [Reference Citation Analysis]
51 Stuschke M, Sarbia M. Neoadjuvante Radiochemotherapie und Responsepr�diktion. Onkologe 2004;10:1179-90. [DOI: 10.1007/s00761-004-0784-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]